XTAE
NVLG
Market cap133mUSD
Oct 09, Last price
77.70ILS
1D
-0.51%
1Q
16.32%
IPO
-53.56%
Name
Novolog Pharm Up 1966 Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment. The Healthcare Services division provides personalized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies. The Digital division identifies and develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics. In addition, the company provides appointment scheduling, calendar management, and telemedicine meeting management. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.
Key people
Rami Dar
Chairman of the Board · since 2018
Eran Taus
Chief Executive Officer · since 2017
Ofer Amar
Chief Executive Officer of a Subsidiary · since 2017
Rafi Friedman
Chief Executive Officer of a Subsidiary · since 2018
Boaz Gershon
Chief Executive Officer of a Subsidiary · since 1999
Ran Laor
Executive Vice President - Finance · since 2011
Ofir Shani Sharabani
Vice President-Information Systems · since 2018
Assaf Vardi
Vice President - Business Development, Sales & Marketing · since 2017
Sivan Raz
Vice President of Human Resources · since 2017
Internal Audit · since 2017
Director · since 2019
Nitay Tal
Director · since 2016
David Ben Ami
External Director · since 2017
Miriam Naveh
External Director · since 2017
Independent Director · since 2013
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||